Grifols, S.A. (NASDAQ:GRFS) Shares Acquired by Jane Street Group LLC

Jane Street Group LLC lifted its position in Grifols, S.A. (NASDAQ:GRFS - Free Report) by 87.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 76,729 shares of the biotechnology company's stock after buying an additional 35,901 shares during the period. Jane Street Group LLC's holdings in Grifols were worth $571,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of GRFS. R Squared Ltd purchased a new position in shares of Grifols in the 4th quarter worth approximately $28,000. Blue Trust Inc. grew its position in shares of Grifols by 254.0% in the 4th quarter. Blue Trust Inc. now owns 6,927 shares of the biotechnology company's stock worth $52,000 after buying an additional 4,970 shares during the last quarter. Tower Research Capital LLC TRC grew its position in shares of Grifols by 354.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,124 shares of the biotechnology company's stock worth $60,000 after buying an additional 6,335 shares during the last quarter. First Trust Advisors LP purchased a new position in shares of Grifols in the 4th quarter worth approximately $75,000. Finally, Envestnet Portfolio Solutions Inc. acquired a new stake in Grifols in the 4th quarter worth approximately $77,000.

Grifols Stock Performance

GRFS stock traded down $0.08 during trading on Friday, reaching $8.28. The company had a trading volume of 313,652 shares, compared to its average volume of 1,159,411. The firm has a 50-day simple moving average of $7.35 and a 200-day simple moving average of $7.57. The company has a market cap of $5.69 billion, a price-to-earnings ratio of 7.08 and a beta of 0.44. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.79 and a current ratio of 2.26. Grifols, S.A. has a twelve month low of $5.79 and a twelve month high of $9.96.

Analyst Ratings Changes

A number of research firms recently commented on GRFS. Wall Street Zen upgraded shares of Grifols from a "hold" rating to a "buy" rating in a research note on Friday, May 23rd. Morgan Stanley began coverage on shares of Grifols in a research note on Wednesday, February 12th. They issued an "overweight" rating for the company.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.